{
    "info": {
        "nct_id": "NCT04432584",
        "official_title": "A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamic and Efficacy of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors",
        "inclusion_criteria": "* Body weight ≥ 40 kg at screening (pediatric participants with body weight < 40 kg)\n* Treated with eculizumab or ravulizumab for PNH for at least 3 months prior to Day 1\n* Lactate Dehydrogenase Levels ≤ 2x the upper limit of normal (ULN) at screening\n* Willingness and ability to comply with all study visits and procedures\n* Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry\n* Vaccination against Neisseria meningitidis serotypes A, C, W, and Y < 3 years prior to initiation of study treatment; or, if not previously done, vaccination administered no later than one week after the first drug administration\n* Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for 10.5 months after the final dose of crovalimab or for 3 months after the final dose of eculizumab (or longer if required by the local product label)\nHealthy volunteers allowed\nMust have minimum age of 2 Years",
        "exclusion_criteria": "* History of allogeneic bone marrow transplantation\n* History of myelodysplastic syndrome with Revised International Prognostic Scoring System (IPSS-R) prognostic risk categories of intermediate, high and very high\n* Pregnant or breastfeeding, or intending to become pregnant during the study, within 10.5 months after the final dose of crovalimab, or 3 months after the final dose of eculizumab (or longer if required by the local product label)\n* Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever was greater: participants enrolled in an eculizumab or ravulizumab interventional study are eligible provided they fulfill eligibility (e.g., are willing and able to comply with the study assessments) and stop their participation in current trial before randomisation/enrolment\n* Positive for Active Hepatitis B and C infection (HBV/HCV)\n* Concurrent disease, treatment, procedure, or surgery or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study\n* History of or ongoing cryoglobulinemia at screening",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Willingness and ability to comply with all study visits and procedures",
            "criterions": [
                {
                    "exact_snippets": "Willingness ... to comply with all study visits and procedures",
                    "criterion": "compliance with study visits and procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ability to comply with all study visits and procedures",
                    "criterion": "compliance with study visits and procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Body weight ≥ 40 kg at screening (pediatric participants with body weight < 40 kg)",
            "criterions": [
                {
                    "exact_snippets": "Body weight ≥ 40 kg at screening",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "kg"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "pediatric participants with body weight < 40 kg",
                    "criterion": "body weight (pediatric participants)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 2 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 2 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lactate Dehydrogenase Levels ≤ 2x the upper limit of normal (ULN) at screening",
            "criterions": [
                {
                    "exact_snippets": "Lactate Dehydrogenase Levels ≤ 2x the upper limit of normal (ULN) at screening",
                    "criterion": "Lactate Dehydrogenase Levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for 10.5 months after the final dose of crovalimab or for 3 months after the final dose of eculizumab (or longer if required by the local product label)",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive_potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for 10.5 months after the final dose of crovalimab or for 3 months after the final dose of eculizumab (or longer if required by the local product label)",
                    "criterion": "contraception or abstinence",
                    "requirements": [
                        {
                            "requirement_type": "behavioral commitment",
                            "expected_value": [
                                "abstinence from heterosexual intercourse",
                                "use of contraception"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the treatment period",
                                "for 10.5 months after the final dose of crovalimab",
                                "for 3 months after the final dose of eculizumab (or longer if required by the local product label)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vaccination against Neisseria meningitidis serotypes A, C, W, and Y < 3 years prior to initiation of study treatment; or, if not previously done, vaccination administered no later than one week after the first drug administration",
            "criterions": [
                {
                    "exact_snippets": "Vaccination against Neisseria meningitidis serotypes A, C, W, and Y < 3 years prior to initiation of study treatment",
                    "criterion": "Neisseria meningitidis serotypes A, C, W, and Y vaccination",
                    "requirements": [
                        {
                            "requirement_type": "time since vaccination",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if not previously done, vaccination administered no later than one week after the first drug administration",
                    "criterion": "Neisseria meningitidis serotypes A, C, W, and Y vaccination",
                    "requirements": [
                        {
                            "requirement_type": "administration timing",
                            "expected_value": "no later than one week after the first drug administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry",
            "criterions": [
                {
                    "exact_snippets": "Documented diagnosis of PNH",
                    "criterion": "paroxysmal nocturnal hemoglobinuria (PNH) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed by high sensitivity flow cytometry",
                    "criterion": "PNH diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "high sensitivity flow cytometry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treated with eculizumab or ravulizumab for PNH for at least 3 months prior to Day 1",
            "criterions": [
                {
                    "exact_snippets": "Treated with eculizumab or ravulizumab for PNH",
                    "criterion": "treatment with eculizumab or ravulizumab for PNH",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 3 months prior to Day 1",
                    "criterion": "duration of treatment with eculizumab or ravulizumab for PNH",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History of myelodysplastic syndrome with Revised International Prognostic Scoring System (IPSS-R) prognostic risk categories of intermediate, high and very high",
            "criterions": [
                {
                    "exact_snippets": "History of myelodysplastic syndrome",
                    "criterion": "myelodysplastic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Revised International Prognostic Scoring System (IPSS-R) prognostic risk categories of intermediate, high and very high",
                    "criterion": "IPSS-R prognostic risk category",
                    "requirements": [
                        {
                            "requirement_type": "category",
                            "expected_value": [
                                "intermediate",
                                "high",
                                "very high"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent disease, treatment, procedure, or surgery or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study",
            "criterions": [
                {
                    "exact_snippets": "Concurrent disease ... that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study",
                    "criterion": "concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study or pose additional risk or preclude safe participation/completion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent ... treatment ... that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study",
                    "criterion": "concurrent treatment",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study or pose additional risk or preclude safe participation/completion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent ... procedure ... that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study",
                    "criterion": "concurrent procedure",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study or pose additional risk or preclude safe participation/completion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent ... surgery ... that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study",
                    "criterion": "concurrent surgery",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study or pose additional risk or preclude safe participation/completion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study",
                    "criterion": "abnormality in clinical laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study or pose additional risk or preclude safe participation/completion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allogeneic bone marrow transplantation",
            "criterions": [
                {
                    "exact_snippets": "History of allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding, or intending to become pregnant during the study, within 10.5 months after the final dose of crovalimab, or 3 months after the final dose of eculizumab (or longer if required by the local product label)",
            "criterions": [
                {
                    "exact_snippets": "Pregnant or breastfeeding",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intending to become pregnant during the study, within 10.5 months after the final dose of crovalimab, or 3 months after the final dose of eculizumab (or longer if required by the local product label)",
                    "criterion": "pregnancy intention",
                    "requirements": [
                        {
                            "requirement_type": "intention to become pregnant",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame after final dose of crovalimab",
                            "expected_value": {
                                "operator": "<",
                                "value": 10.5,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "time frame after final dose of eculizumab",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever was greater: participants enrolled in an eculizumab or ravulizumab interventional study are eligible provided they fulfill eligibility (e.g., are willing and able to comply with the study assessments) and stop their participation in current trial before randomisation/enrolment",
            "criterions": [
                {
                    "exact_snippets": "Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever was greater",
                    "criterion": "participation in another interventional treatment study with an investigational agent or use of any experimental therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last participation/use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants enrolled in an eculizumab or ravulizumab interventional study are eligible provided they fulfill eligibility (e.g., are willing and able to comply with the study assessments) and stop their participation in current trial before randomisation/enrolment",
                    "criterion": "current participation in eculizumab or ravulizumab interventional study",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment of eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness and ability to comply with study assessments",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cessation of participation in current trial before randomisation/enrolment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of or ongoing cryoglobulinemia at screening",
            "criterions": [
                {
                    "exact_snippets": "History of or ongoing cryoglobulinemia at screening",
                    "criterion": "cryoglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence at screening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Positive for Active Hepatitis B and C infection (HBV/HCV)",
            "criterions": [
                {
                    "exact_snippets": "Positive for Active Hepatitis B ... (HBV",
                    "criterion": "active Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Positive for Active ... Hepatitis C infection (HCV)",
                    "criterion": "active Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}